



## Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

September 25, 2025

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.

**Webinar:** Developing Novel Non-Opioid Treatments for Pain: An Overview of Xenon's Nav1.7 and Kv7 Programs

**Date:** Monday, October 6, 2025

**Time:** 11:30 AM – 12:30 PM Eastern Time

**Webcast:** [Register here](#)

**Format:** Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to [investors@xenon-pharma.com](mailto:investors@xenon-pharma.com).

A live webcast of the webinar will be available on the "[Investors](#)" section of Xenon's website and posted for replay following the event. The above listed date and time are subject to change.

### About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit [www.xenon-pharma.com](http://www.xenon-pharma.com) and follow us on [LinkedIn](#) and [X](#).

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

### Contact:

Colleen Alabiso  
Senior Vice President, Corporate Affairs  
(617) 671-9238  
Media: [media@xenon-pharma.com](mailto:media@xenon-pharma.com)  
Investors: [investors@xenon-pharma.com](mailto:investors@xenon-pharma.com)



Source: Xenon Pharmaceuticals Inc.